JACC:心衰患者心脏康复治疗,你知道多少?

2015-09-01 张旭栋 MedSci原创

肯塔基,路易斯维尔大学医学院,Golwala H等人研究了心衰患者中心脏康复训练的使用率,趋势。其结果发表在8月份 Journal of the American College of Cardiology期刊上。背景:目前指南推荐病情稳定的门诊心脏衰竭(HF)患者进行心脏康复训练(CR);然而,现实世界中,心衰患者与心脏康复治疗相关的治疗趋势及其影响因素并不完全已知。目的:这项研究旨在评估失代偿

肯塔基,路易斯维尔大学医学院,Golwala H等人研究了心衰患者中心脏康复训练的使用率,趋势。其结果发表在8月份 Journal of the American College of Cardiology期刊上。
背景:目前指南推荐病情稳定的门诊心脏衰竭(HF)患者进行心脏康复训练(CR);然而,现实世界中,心衰患者与心脏康复治疗相关的治疗趋势及其影响因素并不完全已知。

目的:这项研究旨在评估失代偿心衰出院患者心脏康复的使用率,趋势以及影响因素。

方法:使用的数据来自国家心衰指南,研究评估了2005年至2014年间,射血分数降低型心衰(HFrEF)和射血分数保留型心衰(HFpEF)患者出院后,其心脏康复训练的趋势。同时,研究通过多变量分析评估了患者、医院等级与心脏康复训练之间的联系。

结果:105619例心衰患者(48%为HFrEF,52%为HFpEF)中,10.4%的患者(12.2%为HFrEF,8.8%为HFpEF)出院后接受了心脏康复治疗。研究期间, 观察到HFpEF和HFrEF患者心脏康复治疗比例有显著的提升(p<0.0001,HFrEF,HFpEF)。与出院后未行心脏康复治疗的患者相比,年轻人(主要是男性)在出院后更愿意接受基于证据的心衰治疗。多变量分析后显示,年轻患者,住院患者如冠状动脉旁路移植术,经皮冠状动脉介入和心脏瓣膜手术的患者更愿意接受心脏康复治疗。

结论:因心衰住院最后出院的患者中,只有10%的患者愿意接受心脏康复治疗。心脏康复治疗接受程度随着HFrEF和HFpEF患病时间的延长而增加。应该使用额外新的治疗策略从而提高心衰患者和医生对于心脏康复治疗获益的意识。

原始出处:

Golwala H, Pandey A, Ju C, Butler J, Yancy C, Bhatt DL, Hernandez AF, Fonarow GC (2015) Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure: Findings From Get With The Guidelines-Heart Failure Registry. Journal of the American College of Cardiology 66 (8):917-926. doi:10.1016/j.jacc.2015.06.1089

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=292572, encodeId=fcc52925e289, content=很不错哦.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 03 10:16:36 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853404, encodeId=4a7f18534040c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 31 19:19:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325097, encodeId=2597132509e8e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Sep 03 09:19:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373291, encodeId=0ebe13e3291ac, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Sep 03 09:19:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36322, encodeId=0e2b36322dd, content=……哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Sep 01 20:39:00 CST 2015, time=2015-09-01, status=1, ipAttribution=)]
    2018-03-03 owlhealth

    很不错哦.学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=292572, encodeId=fcc52925e289, content=很不错哦.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 03 10:16:36 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853404, encodeId=4a7f18534040c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 31 19:19:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325097, encodeId=2597132509e8e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Sep 03 09:19:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373291, encodeId=0ebe13e3291ac, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Sep 03 09:19:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36322, encodeId=0e2b36322dd, content=……哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Sep 01 20:39:00 CST 2015, time=2015-09-01, status=1, ipAttribution=)]
    2016-07-31 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=292572, encodeId=fcc52925e289, content=很不错哦.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 03 10:16:36 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853404, encodeId=4a7f18534040c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 31 19:19:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325097, encodeId=2597132509e8e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Sep 03 09:19:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373291, encodeId=0ebe13e3291ac, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Sep 03 09:19:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36322, encodeId=0e2b36322dd, content=……哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Sep 01 20:39:00 CST 2015, time=2015-09-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=292572, encodeId=fcc52925e289, content=很不错哦.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 03 10:16:36 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853404, encodeId=4a7f18534040c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 31 19:19:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325097, encodeId=2597132509e8e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Sep 03 09:19:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373291, encodeId=0ebe13e3291ac, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Sep 03 09:19:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36322, encodeId=0e2b36322dd, content=……哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Sep 01 20:39:00 CST 2015, time=2015-09-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=292572, encodeId=fcc52925e289, content=很不错哦.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Mar 03 10:16:36 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853404, encodeId=4a7f18534040c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 31 19:19:00 CST 2016, time=2016-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325097, encodeId=2597132509e8e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Sep 03 09:19:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373291, encodeId=0ebe13e3291ac, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Sep 03 09:19:00 CST 2015, time=2015-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36322, encodeId=0e2b36322dd, content=……哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=MedSci客户端网友, createdTime=Tue Sep 01 20:39:00 CST 2015, time=2015-09-01, status=1, ipAttribution=)]
    2015-09-01 MedSci客户端网友

    ……哪里

    0

相关资讯

JACC Cardiovasc Interv:新型ARTO系统治疗功能性二尖瓣返流安全有效

新型ARTO系统可改善二尖瓣返流(FMR),因此,本研究评估了新型ARTO系统对心力衰竭患者和功能性二尖瓣返流的治疗效果。 MAVERIC试验是一项前瞻性,非随机化的研究。关键入选标准为患者均为收缩性心衰、NYHA心功能II~IV级、功能性二尖瓣返流等级大于2级、左心室射血分数小于等于40%、左室舒张末期内径在50 mm~75 mm之间。主要安全性终点是30天主要不良事件,有效性终点为二尖瓣返流

心脏病重大里程碑!诺华心衰药Entresto(LCZ696)获FDA批准!

瑞士制药巨头诺华(Novartis)监管方面收获重大里程碑,该公司备受瞩目的慢性心衰药物Entresto(前称LCZ696)近日提前6周获得FDA批准,用于射血分数降低的心力衰竭(heart failure)患者,降低心血管死亡和心衰住院风险。Entresto是一种首创新药,以多种方式作用于心脏的神经内分泌系统,该药是过去25年内心衰治疗领域的一个伟大突破,有望成功动摇过去10年未被修改的心衰治疗

《急性心衰院前和院内早期管理指南》发布及要点

5月21日,《欧洲心脏杂志》(European Heart Journal)刊发了由欧洲心脏学会(ESC)心力衰竭委员会、欧洲急诊治疗学会和流行病学急诊治疗学会联合制定的《急性心力衰竭院前和院内早期的管理指南》(简短版本). 一、急性心衰早期诊疗指南之病房治疗要点 病房治疗及ICU/CCU治疗要点 1.若患者存在显著呼吸困难或血流动力学不稳定状态,应将患者安置于可立即开展心肺复

Nature Commun:小分子可促进缓解心脏衰竭

在心脏细胞中,心肌肌质网的钙离子相关的ATP合成酶(SERCA2a)的表达和活性的降低,被认为是心脏衰竭的标志。这个酶(SERCA2a)是一个与钙离子循环相关的关键性转运离子泵。之前他们发现了一种转录后修饰,即可反转的SUMO化修饰(类似于泛素化修饰),可以调节酶SERCA2a的功能进而影响心脏的功能。这种SUMO修饰可能在多方面影响着细胞的功能。就这个酶SERCA2a而言,存在着多种小的SUMO

JACC Heart Fail:急性失代偿性心衰(ADHF)患者β受体阻滞剂治疗不能停

以往的研究中,显示停用β受体阻滞剂会增加急性失代偿性心衰(ADHF)患者的死亡率和再入院风险,但并没有进行全面的分析。本研究评估并分析了β受体阻滞剂对急性失代偿性心衰(ADHF)患者的影响。 研究人员通过检索PubMed, EMBASE和COCHRANE电子数据库收纳了来自2000年到2015年1月期间发表的相关研究,这些研究主要比较继续和中断β受体阻滞剂治疗的急性失代偿性心衰研究。 共5项观

Hepatology:非酒精性脂肪肝患者可能导致心衰风险

非酒精性脂肪肝(NAFLD)和心力衰竭(HF)导致高心血管死亡率。非酒精性脂肪肝(NAFLD)与亚临床心肌重构及功能障碍是否相关,目前尚未知晓。 研究人员对2713名CARDIA患者进行横断面多中心分析。所收纳的患者中有8.8%为女性,48%为黑人,NAFLD患病率为10%(n=271)。研究人员通过计算机断层扫描(CT)进行肝部脂肪量化,通过超声斑点追踪成像技术测定心肌